Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

New mutations in HFE2 and TFR2 genes causing non HFE-related hereditary hemochromatosis

  • Hernández, Gonzalo
  • Ferrer, Xènia
  • Venturi, Veronica
  • Musri, Melina
  • Floor Pilquil, Martin
  • Muñoz-Torres, Pau Marc
  • Hernandez Rodríguez, Ines
  • Ruiz Mínguez, M. Angels
  • KELLEHER, NICHOLAS
  • Pelucchi, Sara
  • Piperno, Alberto
  • Plensa Alberca, Esther
  • Gener-Ricos, Georgina
  • Cañamero Giró, Eloi
  • Pérez-Montero, Santiago
  • Tornador, Cristian
  • Villà-Freixa, Jordi
  • Sanchez-Fernandez, Mayka
This study was supported by the grant RTI-2018-101735-B-I100 (MCI/AEI/FEDER, EU) from the Spanish Ministry of Science and Innovation (MICINN) to M.S. G.H. is supported by funds provided by the APU and ADISCON Patient associations. X.F.-C. is partially supported by funds provided by the grant RTI-2018-101735-B-I100 (MCI/AEI/FEDER, EU). V.V. is supported by funds provided by APU and ADISCON patient associations and is currently supported by funds provided by UIC postdoctoral scholarship and by funds provided by RETOS COLABORACION grant RTC2019-007074-1 (MCI/AEI/FEDER, EU) from the Spanish Ministry of Science and Innovation (MICINN). The work by M.F.P., P.M.M.T. and J.V.-F. has been developed within the BIO2017-83650-P project, funded by the Spanish Subprograma Estatal de Generación del Conocimiento. M.M. is supported by a Marie Curie Fellowship grant from the European Commission., Hereditary hemochromatosis (HH) is an iron metabolism disease clinically characterized by excessive iron deposition in parenchymal organs such as liver, heart, pancreas, and joints. It is caused by mutations in at least five different genes. HFE hemochromatosis is the most common type of hemochromatosis, while non-HFE related hemochromatosis are rare cases. Here, we describe six new patients of non-HFE related HH from five different families. Two families (Family 1 and 2) have novel nonsense mutations in the HFE2 gene have novel nonsense mutations (p.Arg63Ter and Asp36ThrfsTer96). Three families have mutations in the TFR2 gene, one case has one previously unreported mutation (Family A—p.Asp680Tyr) and two cases have known pathogenic mutations (Family B and D—p.Trp781Ter and p.Gln672Ter respectively). Clinical, biochemical, and genetic data are discussed in all these cases. These rare cases of non-HFE related hereditary hemochromatosis highlight the importance of an earlier molecular diagnosis in a specialized center to prevent serious clinical complications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Haemochromatosis patients' research priorities: Towards an improved quality of life

  • Romero Cortadellas, Lídia
  • Venturi, Veronica
  • Martín-Sánchez, Juan Carlos
  • Toska, Ketil
  • Prince, Dianne
  • Butzeck, Barbara
  • Porto, Graça
  • Thorm Milman, Nils
  • HI/EFAPH Survey Committee
  • Sanchez-Fernandez, Mayka
Ministerio de Ciencia e Innovación, Grant/Award Number: RTC2019‐007074‐1; Generalitat de Catalunya, Grant/Award Number: 2020FI‐B00038; Agencia Estatal de Investigación, Grant/Award Number: PID2021‐122436OB‐I00; APU and ADISCON patient associations; UIC postdoctoral scholarship; RETOS COLABORACION Grant, Background: Chronic diseases are associated with a range of functional and psychosocial consequences that can adversely affect patients' quality of life (QoL). Haemochromatosis (HC) is a genetically heterogeneous disorder characterized by chronic iron overload that can ultimately lead to multiple organ dysfunction. Clinical diagnosis remains challenging due to the nonspecificity of symptoms and a lack of confirmatory genotyping in a substantial proportion of patients. Illness perception among HC patients has not been extensively investigated, lacking relevant information on how to improve their QoL. Methods: We present the results of the first worldwide survey conducted in nearly 1500 HC respondents, in which we collected essential demographic information and identified the aspects that concern HC patients the most. Results: Out of all the participants, 45.3% (n = 676) voiced their concern about physical and psychological consequences such as HC-related arthropathies, which can ultimately affect their social functioning. A similar proportion of patients (n = 635, 42.5%) also consider that better-informed doctors are key for improved HC disease management. Taking a patient-centred approach, we expose differences in patients' disease perspective by social and economic influences. Conclusions: We identify potential targets to improve patients' health-related QoL and reflect on strategic measures to foster gender equity in access to health resources. Finally, we make a call for a highly coordinated effort across a range of public policy areas to empower participants in the HC research process and design. Patient or Public Contribution: Nearly 1500 patients with hereditary HC responded to an anonymized online survey in which research and clinical priorities were addressed regarding this chronic and rare disease., info:eu-repo/semantics/publishedVersion